2013
Pertuzumab: Optimizing HER2 Blockade
Metzger-Filho O, Winer EP, Krop I. Pertuzumab: Optimizing HER2 Blockade. Clinical Cancer Research 2013, 19: 5552-5556. PMID: 23942091, DOI: 10.1158/1078-0432.ccr-13-0518.Peer-Reviewed Original ResearchConceptsBreast cancerAdvanced HER2-positive breast cancerHER2-positive breast cancerRecombinant humanized monoclonal antibodyAddition of pertuzumabTrastuzumab/pertuzumabPhase III studyProgression-free survivalFirst-line treatmentMetastatic breast cancerRisk of mortalityHumanized monoclonal antibodyHeterodimerization of HER2EGF receptorMechanism of actionHER2 blockadeIII studyClinical dataHER familyHER2-HER3 heterodimersPertuzumabDrug AdministrationMonoclonal antibodiesU.S. FoodHER2-HER3
2009
Mechanisms of trastuzumab resistance in breast cancer.
Tolaney SM, Krop IE. Mechanisms of trastuzumab resistance in breast cancer. Anti-Cancer Agents In Medicinal Chemistry 2009, 9: 348-55. PMID: 19275526, DOI: 10.2174/1871520610909030348.Peer-Reviewed Original ResearchConceptsBreast cancerTrastuzumab resistanceHER2-positive metastatic breast cancerHER2-positive breast cancerDevelopment of trastuzumabOutcomes of patientsTrastuzumab-based therapyMetastatic breast cancerInvasive breast cancerHER2/neu geneHumanized monoclonal antibodyPoor patient outcomesNovel therapeutic agentsPatient outcomesTherapeutic agentsPatientsTrastuzumabCancerMonoclonal antibodiesAntitumor activityNeu genePotential mechanismsOutcomesSignificant improvementExtracellular domain
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply